AI is supporting new approaches to diabetes care through early detection, risk prediction, and personalized treatment. By analyzing clinical, glucose monitoring, lifestyle, and patient data, AI can support treatment planning, self-management, and continuous monitoring through digital health tools and wearable devices.
The report includes:
- Impact analysis of artificial intelligence (AI) on the global diabetes market
- Case studies for successful integration of AI and machine learning in early diagnosis, glucose monitoring, treatment optimization and patient management
- Highlights of AI adoption trends across major geographical regions, as well as disruptions caused by AI across key endocrinology, medical devices and digital health industry verticals
- AI’s role in personalized care, clinical decision support, disease management and patient engagement
- Review of AI impact on the various stages of the global diabetes value chain and supply chain analysis
- Competitive landscape featuring key strategic initiatives, market spendings and an investment outlook
Table of Contents
Chapter 1 Key Use Cases for AI Adoption in Diabetes- Overview
- Case Studies
- Case 1: Diabetes Pharmaceuticals
- Case 2: Glucose Monitoring Device Technologies
- Case 3: Insulin Delivery Device Technologies
- Adoption Trends by Region
- Adoption Trends in North America
- Adoption Trends in Europe
- Adoption Trends in Asia-Pacific
- Adoption Trends in the Rest of the World
- Impact of AI on Key Industry Verticals
- Drug Discovery and Development
- Glucose Monitoring
- Insulin Delivery Systems
- Impact of AI on Various Stages of the Supply Chain
- Research and Development
- Manufacturing
- Demand Forecasting and Inventory Management
- Patient Access
- Overview
- Market Spending and Forecasting Analysis
- Market Spending and Forecasting Analysis
- Key Spending by Diabetes Therapeutics and Diagnostics Companies on AI
- VC Investment in AI Focused on Relevant Technologies and Products
- VC Investments
- Abbreviations Used in the Report
Table 1: Key Initiatives by Companies on AI, 2024-2026
Table 2: Key Spending by Companies on AI-Based Diabetes Therapeutics and Diagnostics, 2024-2025
Table 3: Abbreviations Used in This Report
List of Figures
Figure 1: Impact of AI on Value Chain
